The Pre-Filled Syringes Market: 2023 – 2033 – Opportunities, Challenges, Strategies & Forecasts

Release Date: April 2023
Number of Pages: 306
Number of Tables and Figures: 111

Synopsis: A pre-filled syringe (PFS) is a single-dose disposable syringe which comes pre-filled with the substance to be injected. Pre-filled syringes constitute as one of the fastest growing segments of the injectable drug delivery ecosystem, with therapeutic applications ranging from vaccines, biologics, and biosimilars. PFS offer significant benefits over the traditional "vial and syringe" format, by increasing dosing accuracy, safety and convenience.
In addition, pre-filled syringes also offer a variety of economic benefits to pharmaceutical companies including a reduction in drug overfill and waste, which increases the saleable yield of the API (Active Pharmaceutical Ingredient).
SNS Research estimates that the market for pre-filled syringes will account for nearly $8.1 Billion in revenue by the end of 2023. Despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years.  

The “Pre-Filled Syringes Market: 2023 – 2033 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the pre-filled syringes ecosystem including technology, market drivers, challenges, investment potential, leading therapies, use cases, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for pre-filled syringe unit sales from 2023 through to 2033. The forecasts are further segmented for 4 horizontal submarkets, 9 drug classes, 5 regions and 15 leading countries.
​
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 

Single User License: USD 3,000

Company Wide License (Single Site): USD 4,500

Company Wide License (Global Site): USD 7,500

Key Findings:
The report has the following key findings:
  • SNS Research estimates that the market for pre-filled syringes will account for nearly $8.1 Billion in revenue by the end of 2023. Despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years. 
  • A growing number of injectable drugs and vaccines, including blockbusters – such as Adalimumab (Humira) and Etanercept (Enbrel) – are being delivered in the form of pre-filled syringes and pens.
  • Although glass based pre-filled syringes continue to dominate the market by a significant margin, the demand for plastic syringes is gradually increasing to address specific applications – as evident from ongoing investments by manufacturers such as SCHOTT to increase their pre-fillable polymer syringe production capacity.
  • Many pre-filled syringe manufacturers now offer integrated automatic needle shielding or retractable needle options. In addition, specialist manufacturers have developed dual and multi-chambered syringes to cater for drugs that must be reconstituted at the point of delivery.

Topics Covered:
The report covers the following topics:
  • Pre-filled syringes ecosystem
  • Market drivers and barriers
  • Technology, safety mechanisms and key trends
  • Pen systems and auto-injectors
  • Industry roadmap and value chain
  • Analysis of leading drug classes and pre-filled syringe therapies
  • Profiles and strategies of over 100 leading ecosystem players, including pre-filled syringe manufacturers and pharmaceutical giants
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2023 till 2033

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Material
    • Glass
    • Plastic
  • Injector Type
    • Conventional
    • Pen Systems & Auto-Injectors
  • Drug Class
    • Antibodies & Fusion Proteins
    • Insulin & Diabetes Therapies
    • Somatropin, Epinephrine & Other Hormones
    • Interferons
    • EPO (Erythropoietin)
    • G-CSF (Granulocyte-Colony Stimulating Factor)
    • Antithrombotics
    • Vaccines
    • Others & Diluents
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Australia
    • Brazil
    • Canada
    • China
    • France
    • Germany
    • India
    • Italy
    • Japan
    • Mexico
    • Russia
    • South Korea
    • Spain
    • UK
    • USA
​
Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the pre-filled syringes opportunity?
  • What factors are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2023 and at what rate will it grow?
  • What trends, challenges and barriers are influencing its growth?
  • Who are the key market players and what are their strategies?
  • Which countries and submarkets will see the highest percentage of growth?
  • How will approvals of new biologics impact the pre-filled syringes market?
  • What are the future prospects of multi chamber pre-filled syringes?
  • How does regulation impact pre-filled syringes?
  • What strategies should pre-filled syringe manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AbbVie
Adamis Pharmaceuticals Corporation
Aesica
Aguettant Nordic
AI Biosciences
Ajinomoto Althea
Ajinomoto Bio-Pharma Services
Aktiv Pharma Group
Alvotech
AMAG Pharmaceuticals
AMAG Pharmaceuticals (subsidiary of Covis Pharma Group)
Amgen
Amneal Pharmaceuticals
Amphastar Pharmaceuticals
AMRI (Albany Molecular Research, Inc.)
Antares Pharma
Antares Pharma (subsidiary of Halozyme)
Apotex
AptarGroup
Aspen Holdings
AST
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Bahrain Pharma
Battelle
Bausch Health
Baxalta
Baxter International
Bayer
BD
Berkshire Sterile Manufacturing (BSM)
Bespak
Biocon
Biocorp
Biogen
Bioneer
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Catalent
CHEMI
Consort Medical
CordenPharma
Corning
Credence MedSystems
Curia
Daikyo Seiko
DALI Medical Devices
Datwyler Sealing Solutions
E3D (Elcam Drug Delivery Devices)
Elcam Medical
Eli Lilly and Company
Enable Injections
Endo International
FAREVA
Ferring Pharmaceuticals
Fischer Clinical Services
Fresenius Kabi
Gerresheimer
Gore (W. L. Gore & Associates)
GSK (GlaxoSmithKline)
Guerbet
Haselmeier
Haselmeier (a medmix brand)
Hikma Pharmaceuticals
Hospira
IBSA (Institut Biochimque SA)
Impax Laboratories
Intas Pharmaceuticals
Ipsen
Italfarmaco
Johnson & Johnson
JSR Life Sciences
Kaléo
Keystone Folding Box Co
Kyowa Hakko Kirin
Laboratorios Farmacéuticos ROVI
Leo Pharma
LTI (Lyophilization Technology, Inc.)
Lubrizol Life Science Health (LLS Health)
Mallinckrodt
MannKind Corporation
Meda Pharmaceuticals
Medac
Medeca Pharma
Medilet
Medtronic
MedXL
Merck and Co.
Merck KGaA
MGC (Mitsubishi Gas Chemical)
Mylan
Nemera
Nipro Corporation
Noble International
Noble International (an Aptar Pharma company)
Nordic Pharma Group
Novartis
Novo Nordisk
Novosanis
Noxilizer
Ompi
OraTech
Orofino Pharmaceuticals Group
Ortho Dermatologics
Oval Medical Technologies
Overlook Industries
Owen Mumford
PA Consulting
Packaging Technologies & Inspection (PTI)
Pfizer
Piramal Enterprises
Recipharm Ab
Regeneron Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Roselabs Group
Samsung Bioepis
Samsung BioLogics
Samsung Group
Sanofi
SCHOTT
Schreiner MediPharm
Seqirus
Shire
SHL Group (Scandinavian Health Limited)
Sinergium Biotech
SiO2 Material Science
SiO2 Medical Products
SMC
SMC/Oval Medical Technologies
Sobi (Swedish Orphan Biovitrum)
Stada Arzneimittel
Stevanato Group
Sun Pharma (Sun Pharmaceutical Industries)
Syntegon
Takeda Pharmaceutical Company
Ten23 Health
Terumo Corporation
Teva Pharmaceutical Industries
U.S. FDA (Food and Drug Administration)
UCB Group
Valeant Pharmaceuticals
Vetter Pharma International
Viatris
Weigao Group (Shandong Weigao Group Medical Polymer Company)
West Pharmaceutical Services
WuXi Biologics
Ypsomed
Yukon Medical
Zeon Corporation
Zogenix​